Impurity Profiling in API Development: What Health Canada's ICH Q3A Requirements Actually Demand

If you’ve ever received a deficiency letter from Health Canada’s Health Products and Food Branch (HPFB), there’s a reasonable chance it mentioned impurity data. Working with pharmaceutical sponsors on New Drug Submissions (NDS) and Abbreviated New Drug Submissions (ANDS), incomplete impurity characterization shows up consistently among the top reasons for first-round deficiency notices. Not gaps in clinical data. Not formulation concerns. Impurity data.

The irony is that the framework isn’t complicated on paper. Canada has adopted ICH Q3A(R2) for new drug substances, Q3B(R2) for drug products, Q3C for residual solvents, and Q3D for elemental impurities — the same harmonized guidelines applied by the FDA, EMA, and Japan’s PMDA. What trips up sponsors, particularly those filing with Health Canada for the first time, is how HPFB reviewers interpret and apply these thresholds in practice. There’s a meaningful gap between reading the guideline and building a package that survives review.

This post walks through the practical reality of impurity profiling for Canadian API submissions: where the framework creates friction, what reviewers actually want to see, and the documentation errors that repeat themselves across submissions.

ICH Q3A(R2) Thresholds: Reporting, Identification, and Qualification in Practice

The three-tier threshold structure in Q3A is conceptually clean. For a drug substance with a maximum daily dose of 2 g/day or less, the thresholds work as follows:

• Reporting threshold: 0.05% — any impurity at or above this level must be listed in your specification and tracked across batches.
• Identification threshold: 0.10% or 1.0 mg/day total daily intake (TDI), whichever is lower — impurities above this require structural elucidation, typically by NMR, MS/MS, or reference standard comparison.
• Qualification threshold: 0.15% or 1.0 mg/day TDI, whichever is lower — impurities at this level require biological safety data or a documented, scientifically sound analogy to a structurally related, toxicologically characterized compound.

For APIs with a maximum daily dose exceeding 2 g/day, the thresholds shift substantially lower — reporting drops to 0.03%, which catches sponsors off guard when working with high-dose formulations. It’s worth mapping your actual dose range against both tables before you design your analytical specifications.

Where submissions fall apart isn’t usually at the reporting level. Most analytical chemists will detect and list anything above 0.05%. The failure is at qualification. Providing a structure and a spectrum is not qualification. Health Canada reviewers expect to see either toxicological data supporting safety at the observed concentration, or a rigorously documented structural analogy to an accepted compound — not a one-line statement that “literature suggests low toxicity.” That kind of commentary generates a follow-up request within weeks.

One additional structural point: Q3A thresholds apply to the drug substance. Degradation products introduced during formulation or shelf life fall under Q3B, which carries its own threshold table and qualification criteria. Combining API process impurities and drug product degradants in a single table without delineating source and regulatory category is a CTD Module 3 error that reviewers flag consistently.

Genotoxic Impurities and the ICH M7 Complication

ICH M7 sits alongside Q3A and creates a separate — and considerably more demanding — framework for impurities that carry structural alerts for genotoxicity. The governing concept is the Threshold of Toxicological Concern (TTC): for genotoxic impurities without compound-specific carcinogenicity data, the acceptable limit for lifetime exposure is 1.5 μg/day. That’s an extremely stringent ceiling when you’re dealing with synthesis intermediates, reactive reagents, or process-related carryover.

For a drug with a 50 mg daily dose, a 1.5 μg/day limit translates to a specification of 0.003% — a level that demands LC-MS/MS methods with validated sensitivity far below what standard HPLC conditions provide. Most routine impurity methods simply aren’t designed to detect at that level, which means genotoxic impurity control often requires a standalone validated method with its own specificity and LOQ data.

Health Canada expects sponsors to conduct a structural alert assessment for every impurity above the reporting threshold. In silico tools — Derek Nexus, Sarah Nexus, or equivalent software — are the accepted approach. The mistake is treating this as a checkbox: a single-page summary stating “no alerts identified” without showing the software output, the structures evaluated, the software version, or the database build used. Reviewers will ask. Document the assessment the same way you’d document any other analytical experiment.

If you’re bridging to a Reference Listed Drug or relying on a foreign Drug Master File to support impurity limits, be aware that Health Canada reviewers require the data to be either in the submission itself or cross-referenced in a way they can access. An FDA-accepted DMF that addresses ICH M7 compliance under the FDA’s framework doesn’t automatically satisfy HPFB’s review requirements. The data needs to be visible and clearly mapped to your specific impurity profile.

Elemental Impurities Under ICH Q3D — Where Canadian Submissions Slip

Canada’s adoption of ICH Q3D for new drug submissions requires a risk assessment covering 24 elemental impurities, with Permitted Daily Exposures (PDEs) established by route of administration. The route-specific PDEs are where we see a disproportionate number of submission errors.

The oral PDE for arsenic is 15 μg/day. The inhalation PDE is 2 μg/day. For lead, both oral and parenteral PDEs are set at 5 μg/day. Tungsten carries an oral PDE of 100 μg/day, but it’s a compound of particular concern for parenteral products because of documented leaching from elastomeric stoppers. These values aren’t interchangeable, and a specification that applies oral PDEs to a parenteral or inhaled formulation will be flagged.

The Q3D risk assessment requires evaluation of three potential elemental impurity sources: the drug substance (from synthesis reagents, catalysts, and manufacturing equipment), excipients, and the container-closure system. Most sponsors do a reasonable job on the first two. Under-documentation of the container-closure contribution — particularly for parenteral products, where stopper, vial, and syringe components all interact directly with the formulation — is the most common gap.

If your risk assessment concludes that no elemental impurities require analytical controls, that conclusion needs to be substantiated. The accepted basis is either historical batch data showing measured levels consistently below 30% of the applicable PDE (the threshold below which routine analytical controls aren’t mandated), or supplier Certificates of Analysis with quantitative elemental data for each relevant element. A compendial heavy metals test using a colorimetric limit method is not adequate elemental characterization under Q3D. Health Canada reviewers know the difference, and they’ll say so.

Structuring a Defensible Impurity Package for Health Canada

A complete impurity package for a Canadian NDS or ANDS needs to address four elements clearly enough that a reviewer can follow your logic without significant cross-referencing between modules.

Batch data from multiple commercial-scale lots. Three batches representing the proposed manufacturing process is the working expectation. Lab-scale data may supplement, but it doesn’t substitute. Select batches that reflect realistic process variability — include the highest-impurity lots you’ve observed, not just the cleanest. If your worst batch drives the specification limit, that’s actually a stronger argument than a limit derived from a batch that may not represent scale-up conditions.

Specifications with limits that are explicitly justified. “NMT 0.10%” is a limit. It’s not a justification. Each individual impurity limit and the total impurity limit need to be anchored to either the Q3A threshold, compound-specific toxicological data, or — where limits are tighter than thresholds — demonstrated analytical method capability. Reviewers will ask why a limit is set where it is. The answer should already be in the submission.

Forced degradation studies that identify degradation-related impurities. Hydrolysis, oxidation, photolysis, and thermal stress conditions are the standard panel. This is where Q3A and Q1A(R2) stability data converge: degradants that appear during forced degradation and exceed identification thresholds need to be characterized and potentially qualified before your NDS is filed. Discovering an uncharacterized degradant in formal stability data at the 12-month timepoint — after submission — generates a pharmaceutical deficiency notice at exactly the moment you don’t want one.

Validated analytical methods with demonstrated specificity at the impurity level. Method validation under ICH Q2(R1) must show that your HPLC or LC-MS/MS method resolves all known impurities from each other and from the API peak under the proposed chromatographic conditions. Specificity data using known impurity reference standards at or near the reporting threshold is the expected standard of evidence. Where reference standards aren’t commercially available, document your attempts to obtain them and the bridging strategy you used.

Getting this right pays forward in a concrete way. Submissions with thorough, well-organized Q3 documentation in Module 3.2.S.3 tend to clear the chemistry review without a pharmaceutical deficiency notice — which, in our experience, can easily represent two to four months of saved review time against the standard HPFB review clock. The investment in building the package properly at the outset is almost always less than the cost of responding to a deficiency mid-review.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• ISO 17025-Accredited Analytical Testing for Pharmaceutical Impurity Characterization — Qalitex Laboratories offers validated HPLC and LC-MS/MS methods supporting impurity profiling for North American drug submissions.
• EU Impurity and API Testing Under EMA and European Pharmacopoeia Guidelines — Care Europe covers EU-specific ICH Q3 implementation and elemental impurity testing requirements for European market authorization applications.